Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 610-954-5 | CAS number: 53075-09-5
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Additional information
There are no data available concerning effects on fertility.
Effects on developmental toxicity
Description of key information
OECD 414, rat, oral (gavage): NOAEL maternal and developmental effects = 1000 mg/kg/d
Additional information
In the key study (BASF SE, 2010), that was performed according to OECD guideline 414 in compliance with GLP, Adamantyltrimethylammoniumhydroxide 20% was administered to pregnant Wistar rats daily by gavage from implantation to one day prior to the expected day of parturition (GD 6 - 19). Analyses confirmed the correctness of the prepared concentrations and the stability of the test substance.
There were no test substance-related effects on the dams concerning mortality, food consumption, body weight, body weight gain, gestational parameters, uterine and placental weights, as well as necropsy observations up to and including a dose of 1000 mg/kg bw/day. The high-dose (1000 mg/kg bw/d) caused transient (for a few minutes) salivation directly after treatment, which was likely to be induced by the bad taste of the test substance or by local irritation in the upper digestive tract of dams. It is not considered to be a sign of systemic toxicity. Salivation was not observed after treatment with lower doses.
Fetal examinations revealed no influence of the test compound on sex distribution of the fetuses and fetal body weights. Adamantyltrimethylammoniumhydroxide 20% shows no direct and specific effect on fetal morphological structures.
In conclusion, the no observed adverse effect level (NOAEL) of Adamantyltrimethylammoniumhydroxide 20% for maternal and prenatal developmental toxicity was determined to be 1000 mg/kg bw/day.
Justification for classification or non-classification
EU classification according to Annex VI of Directive 67/548/EEC:
- Effects on fertility: No classification due to lacking data - Developmental toxicity/teratogenicity: Conclusive, but not sufficient for classification
GHS classification according toAnnex I 1272/2008 CLP (EU GHS):
- Effects on fertility: No classification due to lacking data
- Developmental toxicity/teratogenicity: Conclusive, but not sufficient for classification
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
